Article

November 30, 2012

NOW AVAILABLE: AMCP Fall 2012 Conference Coverage

Highlights from the Academy of Managed Care Pharmacy's 2012 Educational Conference, which took place on October 3-5, 2012, in Cincinnati, Ohio, are available in a newsletter published by The American Journal of Managed Care. Topics discussed include the ways in which heterogeneity shapes therapeutic decisions, patient outcomes, and coverage policies; assessment of the evidence for new medications; and phone-based medication therapy management services.

Highlights from the Academy of Managed Care Pharmacy’s 2012 Educational Conference, which took place on October 3-5, 2012, in Cincinnati, Ohio, are available in a newsletter published by The American Journal of Managed Care. Topics discussed include the ways in which heterogeneity shapes therapeutic decisions, patient outcomes, and coverage policies; assessment of the evidence for new medications; and phone-based medication therapy management services.

To access the publication, please click here or the image below.

AMCP Conference Coverage

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos

Dr Brian Slomovitz

H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview

ASCO 2025

H. John Beardsley, MBA, and Fauzea Hussain, MPH, sitting for a video interview

Samir Shah, MD, MMM, FACR

Dr Brian Slomovitz

Reynold Panettieri, Jr, MD

Dirk Arnold, MD, PhD, medical director, Asklepios Tumour Biology Centre

Jill Feldman, patient, cofounder and president, EGFR Resisters

Related Content

The findings support the use of luspatercept as the first-line standard of care for anemia treatment in patients with MDS. | Image Credit: wanchalerm - stock.adobe.com

June 5th 2025

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

Anjali Vaidya, MD, FACC, FASE, FACP | Image Credit: Temple University Hospital

June 4th 2025

New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide

Maggie L. Shaw Anjali Vaidya, MD, FACC, FASE, FACP

Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.

Managed Care Cast.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL

June 3rd 2025

In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.

Clinician holding piggy bank | Image Credit: Dee Karen - stock.adobe.com

June 2nd 2025

Oncology Biosimilars Offer Potential Relief From Financial Burden of Cancer Care

Brooke McCormick

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the 2025 American Society of Clinical Oncology Annual Meeting.

Related Content

The findings support the use of luspatercept as the first-line standard of care for anemia treatment in patients with MDS. | Image Credit: wanchalerm - stock.adobe.com

June 5th 2025

Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS

Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.

August 29th 2023

The Importance of Examining and Preventing Atrial Fibrillation

At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.

Anjali Vaidya, MD, FACC, FASE, FACP | Image Credit: Temple University Hospital

June 4th 2025

New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide

Maggie L. Shaw Anjali Vaidya, MD, FACC, FASE, FACP

Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.

Managed Care Cast.

June 28th 2022

Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions

Matthew Gavidia

On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.

In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL

June 3rd 2025

In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL

Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.

Clinician holding piggy bank | Image Credit: Dee Karen - stock.adobe.com

June 2nd 2025

Oncology Biosimilars Offer Potential Relief From Financial Burden of Cancer Care

Brooke McCormick

Oncology biosimilars significantly reduce financial toxicity in cancer care, as highlighted in 2 abstracts presented at the 2025 American Society of Clinical Oncology Annual Meeting.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions